Trial Outcomes & Findings for Assessment of Novel Intraocular Injection Guide (NCT NCT02315170)

NCT ID: NCT02315170

Last Updated: 2021-05-05

Results Overview

The VAS is a horizontal line, 100 mm in length, and anchored by word descriptors at each end. The scale scores range from 0mm (no pain) to 100mm (very severe pain). The patient marks on the line the point that they feel represents their perception of their current state (no pain to very severe pain).

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

50 participants

Primary outcome timeframe

one time for about 30 sec or less

Results posted on

2021-05-05

Participant Flow

all subjects presenting for bilateral injection were offered the chance to participate in this clinical trail

eyes were chosen for the novel guide or standard lid speculum using a randomizing table

Unit of analysis: eyes

Participant milestones

Participant milestones
Measure
Intraocular Injection Guide
novel intraocular injection guide is a long, tubular structure consisting of a non-moldable material with a single internal opening. There is a 2x2 square hole located at the bottom of the device where the needle exits the guide and enters the eye intraocular injection guide: The device is 35mm long with tapered edges for an easy grip and it aligns with the curvature of the cornea to ensure that needle entry takes place at the optimal distance for injection
Standard Lid Speculum
Standard wire eyelid speculum standard lid speculum: standard wire lid speculum
Overall Study
STARTED
50 50
50 50
Overall Study
COMPLETED
50 50
50 50
Overall Study
NOT COMPLETED
0 0
0 0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Assessment of Novel Intraocular Injection Guide

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
All Participants
n=50 Participants
Only subjects needing bilateral ocular injections were included in the study. The total number of participants was 50 (100 eyes). Baseline characteristics were identical in both groups. One eye received the treatment with the injection guide while the fellow eye received the treatment with a standard lid speculum.
Age, Categorical
<=18 years
0 Participants
n=99 Participants
Age, Categorical
Between 18 and 65 years
20 Participants
n=99 Participants
Age, Categorical
>=65 years
30 Participants
n=99 Participants
Sex: Female, Male
Female
35 Participants
n=99 Participants
Sex: Female, Male
Male
15 Participants
n=99 Participants

PRIMARY outcome

Timeframe: one time for about 30 sec or less

Population: Total number of subjects is 50 - however as the system here is designed for whole body count (not bilateral organs such as eyes), the total number will appear to be double of actual number of subjects.

The VAS is a horizontal line, 100 mm in length, and anchored by word descriptors at each end. The scale scores range from 0mm (no pain) to 100mm (very severe pain). The patient marks on the line the point that they feel represents their perception of their current state (no pain to very severe pain).

Outcome measures

Outcome measures
Measure
Intraocular Injection Guide
n=50 eyes
novel intraocular injection guide is a long, tubular structure consisting of a non-moldable material with a single internal opening. There is a 2x2 square hole located at the bottom of the device where the needle exits the guide and enters the eye intraocular injection guide: The device is 35mm long with tapered edges for an easy grip and it aligns with the curvature of the cornea to ensure that needle entry takes place at the optimal distance for injection
Standard Lid Speculum
n=50 eyes
Standard wire eyelid speculum standard lid speculum: standard wire lid speculum
Visual Analogue Scale (VAS)
14 mm on the VAS
Standard Deviation 6
33 mm on the VAS
Standard Deviation 7

Adverse Events

Intraocular Injection Guide

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Standard Lid Speculum

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Raj K Maturi MD

Raj K M

Phone: 3178171414

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place